Nexus Finance
AFX.DE Carl Zeiss Meditec AG I | DE0005313704

Company Profile

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

Latest News

Sector Healthcare
Industry Medical Instruments & Supplies
Website https://www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir
Audit Risk 2
Board Risk 6
Overall Risk 7
Market Cap 2.47B
Trailing P/E 20.63
Forward P/E 15.93
Dividend Rate 0.55
Dividend Yield 1.98%
Trailing Annual Div. Rate 0.55
Trailing Annual Div. Yield 1.98%
Trailing EPS 1.37
Forward EPS 1.77
Book Value 23.98
Price-to-Book 1.18
Enterprise-to-Revenue 1.38
Enterprise-to-EBITDA 13.84
Ex-Dividend Date 03/27/2026
Earnings Date 08/06/2026
Earnings Call Date 05/12/2026
Earnings Average 0.38
Earnings Low 0.35
Earnings High 0.4
Revenue Average 540.90M
Revenue Low 528.98M
Revenue High 550.00M
ende